[1] |
Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med, 2021, 384(18):1705-1718. doi: 10.1056/NEJMoa2033400.
doi: 10.1056/NEJMoa2033400
URL
|
[2] |
World Health Organization. Treatment of drug-susceptible tuberculosis: rapid communication. Geneva: World Health Organization, 2021.
|
[3] |
Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946—1986, with relevant subsequent publications. Int J Tuberc Lung Dis, 1999, 3(10 Suppl 2):S231-279.
|
[4] |
Fox W, Mitchison DA. Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis, 1975, 111(3):325-353. doi: 10.1164/arrd.1975.111.3.325.
doi: 10.1164/arrd.1975.111.3.325
|
[5] |
国家药典委员会. 中华人民共和国药典临床用药须知(2010年版). 化学药和生物制品卷. 北京: 中国医药科技出版社, 2021:784-785.
|
[6] |
de Steenwinkel JE, Aarnoutse RE, de Knegt GJ, et al. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. Am J Respir Crit Care Med, 2013, 187(10):1127-1134. doi: 10.1164/rccm.201207-1210OC.
doi: 10.1164/rccm.201207-1210OC
URL
|
[7] |
Rosenthal IM, Tasneen R, Peloquin CA, et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother, 2012, 56(8):4331-4340. doi: 10.1128/AAC.00912-12.
doi: 10.1128/AAC.00912-12
pmid: 22664964
|
[8] |
Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother, 2007, 51(8):2994-2996. doi: 10.1128/AAC.01474-06.
doi: 10.1128/AAC.01474-06
pmid: 17517849
|
[9] |
Svensson EM, Svensson RJ, Te Brake LHM, et al. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clin Infect Dis, 2018, 67(1):34-41. doi: 10.1093/cid/ciy026.
doi: 10.1093/cid/ciy026
pmid: 29917079
|
[10] |
Rosenthal IM, Zhang M, Almeida D, et al. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med, 2008, 178(9):989-993. doi: 10.1164/rccm.200807-1029OC.
doi: 10.1164/rccm.200807-1029OC
URL
|
[11] |
Dooley KE, Bliven-Sizemore EE, Weiner M, et al. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther, 2012, 91(5):881-888. doi: 10.1038/clpt.2011.323.
doi: 10.1038/clpt.2011.323
pmid: 22472995
|
[12] |
Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med, 2014, 371(17):1577-1587. doi: 10.1056/NEJMoa1407426.
doi: 10.1056/NEJMoa1407426
URL
|
[13] |
Nunn AJ, Phillips PP, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis, 2010, 14(2):241-242.
pmid: 20074418
|
[14] |
国家药品监督管理局药品评价中心, 国家药品不良反应监测中心. 关于发布国家药品不良反应监测年度报告(2019年)的通告. 2020-04-10.
|
[15] |
刘旭东, 王炳元. 我国药物性肝损害2003—2008年文献调查分析. 临床误诊误治, 2010, 23(5):487-488. doi: 10.3969/j.issn.1002-3429.2010.z1.004.
doi: 10.3969/j.issn.1002-3429.2010.z1.004
|
[16] |
Zhou Y, Yang L, Liao Z, et al. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese litera-ture including 21,789 patients. Eur J Gastroenterol Hepatol, 2013, 25(7):825-829. doi: 10.1097/MEG.0b013e32835f6889.
doi: 10.1097/MEG.0b013e32835f6889
URL
|
[17] |
Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med, 2002, 137(12):947-954. doi: 10.7326/0003-4819-137-12-200212170-00007.
doi: 10.7326/0003-4819-137-12-200212170-00007
pmid: 12484709
|